241 related articles for article (PubMed ID: 25653020)
1. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
[TBL] [Abstract][Full Text] [Related]
2. Cell membrane associated free kappa light chains are found on a subset of tonsil and in vitro-derived plasmablasts.
Hutchinson AT; Jones DR; McCauley Winter P; Tangye SG; Raison RL
Hum Immunol; 2014 Sep; 75(9):986-90. PubMed ID: 25149546
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
5. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
6. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.
van der Veer MS; de Weers M; van Kessel B; Bakker JM; Wittebol S; Parren PW; Lokhorst HM; Mutis T
Haematologica; 2011 Feb; 96(2):284-90. PubMed ID: 21109694
[TBL] [Abstract][Full Text] [Related]
7. The surface expression of a tumor-associated antigen on human kappa myeloma cells.
Boux HA; Raison RL; Walker KZ; Musgrove E; Basten A
Eur J Immunol; 1984 Mar; 14(3):216-22. PubMed ID: 6423392
[TBL] [Abstract][Full Text] [Related]
8. A monoclonal antibody with selectivity for human kappa myeloma and lymphoma cells which has potential as a therapeutic agent.
Walker KZ; Boux HA; Hayden GE; Goodnow CC; Raison RL
Adv Exp Med Biol; 1985; 186():833-41. PubMed ID: 3931433
[TBL] [Abstract][Full Text] [Related]
9. Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors.
Harada T; Ozaki S; Oda A; Tsuji D; Ikegame A; Iwasa M; Udaka K; Fujii S; Nakamura S; Miki H; Kagawa K; Kuroda Y; Kawai S; Itoh K; Yamada-Okabe H; Matsumoto T; Abe M
PLoS One; 2013; 8(12):e83905. PubMed ID: 24386306
[TBL] [Abstract][Full Text] [Related]
10. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
Tai YT; Horton HM; Kong SY; Pong E; Chen H; Cemerski S; Bernett MJ; Nguyen DH; Karki S; Chu SY; Lazar GA; Munshi NC; Desjarlais JR; Anderson KC; Muchhal US
Blood; 2012 Mar; 119(9):2074-82. PubMed ID: 22246035
[TBL] [Abstract][Full Text] [Related]
11. Activity of thalidomide and lenalidomide in mantle cell lymphoma.
Richardson SJ; Eve HE; Copplestone JA; Dyer MJ; Rule SA
Acta Haematol; 2010; 123(1):21-9. PubMed ID: 19907157
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide.
Nijhof IS; Lammerts van Bueren JJ; van Kessel B; Andre P; Morel Y; Lokhorst HM; van de Donk NW; Parren PW; Mutis T
Haematologica; 2015 Feb; 100(2):263-8. PubMed ID: 25510242
[TBL] [Abstract][Full Text] [Related]
14. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma.
Hutchinson AT; Jones DR; Raison RL
Mol Immunol; 2015 Oct; 67(2 Pt A):89-94. PubMed ID: 25964097
[TBL] [Abstract][Full Text] [Related]
16. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.
Benson DM; Bakan CE; Zhang S; Collins SM; Liang J; Srivastava S; Hofmeister CC; Efebera Y; Andre P; Romagne F; Bléry M; Bonnafous C; Zhang J; Clever D; Caligiuri MA; Farag SS
Blood; 2011 Dec; 118(24):6387-91. PubMed ID: 22031859
[TBL] [Abstract][Full Text] [Related]
17. A sequential cohort study evaluating single-agent KappaMab and KappaMab combined with lenalidomide and low-dose dexamethasone in relapsed and/or refractory kappa light chain-restricted multiple myeloma (AMaRC 01-16).
Spencer A; Kalff A; Shortt J; Quach H; Wallington-Gates C; Reynolds J; Walker P; Harrison SJ; Dunn R; Wellard C
Br J Haematol; 2023 Aug; 202(4):801-811. PubMed ID: 37357593
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab: monoclonal antibody therapy to treat multiple myeloma.
Xia C; Ribeiro M; Scott S; Lonial S
Drugs Today (Barc); 2016 Oct; 52(10):551-560. PubMed ID: 27910963
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6.
Dezorella N; Pevsner-Fischer M; Deutsch V; Kay S; Baron S; Stern R; Tavor S; Nagler A; Naparstek E; Zipori D; Katz BZ
Exp Cell Res; 2009 Jul; 315(11):1904-13. PubMed ID: 19328780
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo characterization of MDX-1401 for therapy of malignant lymphoma.
Cardarelli PM; Moldovan-Loomis MC; Preston B; Black A; Passmore D; Chen TH; Chen S; Liu J; Kuhne MR; Srinivasan M; Assad A; Witte A; Graziano RF; King DJ
Clin Cancer Res; 2009 May; 15(10):3376-83. PubMed ID: 19401346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
